Roche Gets FDA Clearance for cobas BV/CV Assay
Roche FDA clearance cobas BV/CV brings a dual bacterial vaginosis and Candida vaginitis PCR panel to U.S. labs. Roche said on July 24, 2026 that the FDA issued 510(k) clearance for the assay, which returns both results from one vaginal swab on cobas 6800/8800 systems.
Contents10 sections
Key Takeaways
- FDA granted 510(k) clearance for Roche's cobas BV/CV assay on July 24, 2026 (company announcement).
- The PCR test reports BV and CV from one clinician-collected or clinician-instructed self-collected vaginal swab in cobas PCR Media.
- Targets include Gardnerella, Atopobium, Lactobacillus spp., and six Candida species associated with CV.
- Launch on cobas 6800/8800 is expected later in 2026; cobas 5800 is planned via instrument-family policy.
cobas BV/CV at a glance
| Field | Detail |
|---|---|
| Product | cobas BV/CV (Bacterial vaginosis / Candida vaginitis) assay |
| Company | Roche Diagnostics |
| FDA action | 510(k) clearance announced July 24, 2026 |
| Use setting | Professional laboratory use on clinician order |
| Specimen | Vaginal swab in cobas PCR Media (clinician or instructed self-collect) |
| Platforms | cobas 6800/8800; cobas 5800 planned |
| Menu fit | Runs with cobas CT/NG and cobas TV/MG from the same sample |
What did the FDA clear?
Roche said the FDA cleared cobas BV/CV as an in vitro diagnostic PCR assay that provides results for bacterial vaginosis and Candida vaginitis from a single vaginal swab. The test is for professional laboratory use based on a clinician's order and is intended for symptomatic patients.
See Roche's July 24 PR Newswire clearance announcement.
Why does molecular vaginitis testing matter?
Roche cited vaginitis as one of the most common reasons women seek care, with BV affecting about 27% of reproductive-age women in North America and up to 75% of women experiencing Candida vaginitis at least once. Traditional microscopy, pH testing, and clinical observation can lack precision; Roche cited literature putting misdiagnosis near 50%, raising recurrence risk.
U.S. public-health treatment context for vaginal discharge syndromes is summarized in CDC STI Treatment Guidelines on vaginal discharge.
What organisms and workflow does the assay cover?
Roche said real-time PCR detects BV-associated organisms including Gardnerella vaginalis, Atopobium vaginae, and Lactobacillus spp., plus Candida species associated with CV: C. albicans, C. glabrata, C. krusei, C. parapsilosis, C. tropicalis, and C. dubliniensis.
- Sample can also support cobas CT/NG (chlamydia/gonorrhea) and cobas TV/MG (trichomonas/Mycoplasma genitalium) without extra collection
- Roche said the approach aligns with CDC guidance that does not require Candida speciation before first-line therapy
- Additional speciation or susceptibility testing is reserved for persistent or recurrent CV (≥3 episodes in a year) or documented first-line failure
What is the commercial timeline?
Roche said commercial launch is expected later this year on cobas 6800/8800 systems and that it plans to add the cobas 5800 system through FDA's Reagent Replacement and Instrument Family Policy. The clearance expands Roche Diagnostics' sexual-health menu for clinics, hospitals, and reference labs seeking consolidated molecular workflows.
Broader FDA device-clearance context for molecular diagnostics sits with the agency's FDA Medical Devices program pages; labeled intended use will be in the cleared instructions for use.
What remains uncertain?
510(k) clearance establishes substantial equivalence for the cleared intended use; it is not a drug approval and does not by itself prove superiority versus every lab-developed or competitor assay in head-to-head trials. Exact clinical sensitivity/specificity tables belong in the IFU and supporting 510(k) summary, not the launch wire. Pricing, payer coverage, and cobas 5800 timing were not disclosed in the announcement.
Related NovaPharma coverage
- FDA Clears First OTC CGM for Children: Dexcom Expands Stelo
- FDA Activity Round Up July 2026
- FDA approves OTC Rextovy, broadening naloxone access
Frequently Asked Questions
What did the FDA clear for Roche's cobas BV/CV assay?
On July 24, 2026, Roche said the FDA granted 510(k) clearance for the cobas BV/CV assay, a professional-use PCR test that reports bacterial vaginosis and Candida vaginitis results from a single clinician-collected or clinician-instructed self-collected vaginal swab.
Which organisms does cobas BV/CV detect?
Roche said the assay detects DNA targets associated with BV, including Gardnerella vaginalis, Atopobium vaginae, and Lactobacillus spp., plus Candida species linked to CV, including C. albicans, C. glabrata, C. krusei, C. parapsilosis, C. tropicalis, and C. dubliniensis.
Which Roche systems will run cobas BV/CV?
The assay expands the sexual-health menu on cobas 6800/8800 systems and can share a sample with cobas CT/NG and cobas TV/MG tests. Roche plans to add cobas 5800 via FDA's Reagent Replacement and Instrument Family Policy, with commercial launch expected later in 2026.
Primary Sources
Roche pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
This article follows our editorial standards. Report a correction via editorial contact.
